V3 interneurons in the spinal cord are a group of excitatory commissural interneurons that play an important role in producing balanced and stable gaits in animals. We discovered that Sim1-expressing V3 interneurons arise from the ventral-most progenitor domain in the developing neural tube and migrate in a dorso-lateral trajectory to settle into three distinct subpopulations. The most ventral subpopulation projects axons in both an rostral and caudal direction, while the intermediate and dorsal subpopulations are mostly rostrally-projecting. The role of Sim1 as a transcription factor was shown to play a role both in the proper migration and axon projection of V3 interneurons.

Student Number : 0114163J - PhD thesis - Faculty of Health Sciences / HIV-1 gains entry into host cells by binding to CD4 and a coreceptor, predominantly CCR5 or CXCR4. Viruses that use CCR5 are termed R5, those able to use CXCR4 are termed X4 while viruses able to use both coreceptors are referred to as R5X4. Accelerated CD4 decline and disease progression within an infected HIV-1 subtype B infected individual is often associated with the emergence of viruses able to use CXCR4. However, CXCR4 coreceptor usage appears to occur less frequently among HIV-1 subtype C viruses, the most predominant strain circulating globally, including South Africa. The aim of this study was to investigate the genetic determinants of CXCR4 usage in HIV-1 subtype C isolates. The V3 region of the envelope glycoprotein is the major determinant of coreceptor usage. In Chapter 2, 32 subtype C isolates with known phenotypes (16 R5, 8 R5X4 and 8 X4 isolates) were assessed using a subtype C specific V3-heteroduplex tracking assay. Results indicated that there were sufficient genetic differences to discriminate between R5 viruses and those able to use CXCR4 (both R5X4 and X4). In general, R5 isolates had a mobility ratio >0.9 whereas CXCR4-using isolates were usually <0.9. Sequence analysis of the V3 region showed that CXCR4-using viruses were often associated with an increased positive amino acid charge, insertions and loss of a glycosylation site, similar to HIV-1 subtype B. In contrast, where subtype B consensus V3 has a GPGR crown motif irrespective of coreceptor usage, all 16 subtype C R5 viruses had a conserved GPGQ sequence at the tip of the loop, while 12 of the 16 (75%) CXCR4-using viruses had substitutions in this motif, most commonly arginine (R). Thus, the rare occurrence of CXCR4-using viruses in subtype C may be due to the highly conserved nature of the GPGQ crown that may limit the potential for the development of X4 viruses. The usefulness of available genotype-based methods for predicting viral phenotypes in subtype C was explored in Chapter 3. Results indicated that commonly used prediction methods could detect R5 viruses, but were not very sensitive at identifying X4 viruses. We therefore developed a subtype C specific predictor based on position specific scoring matrices (PSSM). Similar methodology, as used in developing the subtype B PSSM, was applied on a training set of 280 subtype C sequences of known phenotype (229 NSI/CCR5 and 51 SI/CXCR4). The C-PSSM had a specificity of 94% (C.I. [92%-96%]) and sensitivity of 75% (C.I. [68%-82%]), indicating that the C-PSSM had improved sensitivity in predicting CXCR4 usage. This method also highlighted amino acid positions within V3 that could contribute differentially to phenotype prediction in subtypes B and C. A reliable phenotype prediction method, such as the C-PSSM, could provide a rapid and less expensive approach to identifying CXCR4 variants, and thus increase our knowledge of subtype C coreceptor usage. In Chapter 4 we examined the genetic changes in full-length gp160 envelope genes of 23 sequential isolates from 5 patients followed for two to three years. Three of the patients' isolates used CCR5 at all time points while 2 patients underwent a coreceptor switch with disease progression. The genetic changes observed over time indicated changes in length of variable loops particularly the V1, V4 and V5 and shifting N-glycosylation sites, particularly in the 2 patients that used CXCR4. Changes in the V3 were only noted in the 2 patients’ that used CXCR4 which included substitutions of specific amino acids including those in the crown and increased amino acid charge in the V3 region. Both of these patients were dually infected suggesting that recombination may contribute to the rapid emergence of X4 viruses. The in vitro and in vivo development of CXCR4 usage was analysed in a pediatric patient that experienced a coreceptor switch during disease progression (Chapter 5). Biological and molecular clones were generated and the V1-V5 regions sequenced. Analyses of the V3 region indicated that the evolution to CXCR4 usage happens in a step-wise manner that included increased charge and changes in the crown motif. The intermediate variants with predicted dualtropism were also associated with increased V1-V2 lengths, suggesting that other regions may contribute to coreceptor switching. Furthermore, the development of CXCR4 usage within this patient was due to two mutational pathways, in which one resulted in R5X4 viruses and the other X4 variants. In Chapter 6, the impact and treatment of acute TB on HIV-1 diversity in co-infected patients was investigated, specifically to determine the genetic characteristics of the viral populations present before, during and after TB treatment. Plasma samples from 18 HIV-1 infected patients were analysed using the C2V3 region, six of whom showed a high degree of variation using a V3-HTA and were selected for further analyses. All patients were predicted as R5 with no evidence of coreceptor switching over time. There was no correlation between the degree of genetic diversity and viral load, although both showed fluctuations over time. Phylogenetic and pairwise genetic distance analysis indicated that there was amplification of existing variants in 3 patients while in the other 3 patients there were dramatic shifts in viral populations suggesting selection of viral sub-populations over time. Thus in some co-infected patients, TB can affect HIV-1 genetic heterogeneity although there was no evidence of a shift towards CXCR4 usage despite the presence of an AIDS defining illness. Observations in this study have shown that the V3 region is the major determinant of coreceptor usage within HIV-1 subtype C, similar to HIV-1 subtype B. Characteristics such as increased charge length variability of the V3 region and loss of the glycosylation site within this region are associated with CXCR4 usage. The limited number of X4 viruses in subtype C does suggest some restricting mechanisms for CXCR4 usage. In this study we looked at genetic determinants and found that the rare occurrence of CXCR4-using viruses in subtype C, may be due to the highly conserved nature of the GPGQ crown that may limit the potential for the development of subtype C X4 viruses. Furthermore, the development of CXCR4 usage happened in a step-wise manner, with R5X4 viruses intermediates, in which an increased V1-V2 was observed suggesting that other regions within the envelope protein do contribute to coreceptor usage. Thus, regions such as V1-V2 and V4-V5 did contribute to coreceptor usage, but the V3 region remained the most important determinant of coreceptor usage in HIV-1 subtype C isolates. Collectively these findings have provided important data on the genetic determinants of CXCR4 usage in HIV-1 subtype C and an understanding of how they might evolve within a patient.

Objective: The human immunodeficiency virus type 1 (HIV-1) currently infects over 30 million people worldwide. It uses one of two main co-receptors to infect cells. The primary objective of this thesis is to evaluate genotypic and phenotypic assays for co-receptor usage in the clinical setting and investigate approaches for improvement of these assays. Methods: The concordance of recombinant co-receptor phenotyping assays and the predictive ability of genotype-based methods including the ‘11/25’ rule, position specific scoring matrices (PSSMs), and support vector machines (SVMs) were evaluated in the clinical setting using patient-derived plasma samples. Samples and patient data were evaluated in cross-sectional analyses from a retrospective population-based cohort of HIV-infected individuals enrolled in the HIV/AIDS Drug Treatment Program in British Columbia, Canada. Results: Current implementations of HIV V3 region-based predictors for HIV co-receptor usage tested on patient derived samples are inadequate in the clinical setting, primarily due to low sensitivities as a result of difficult to detect minority species. Recombinant phenotype assays also show discordances when tested against each other on the same set of patient derived samples, raising doubts if any of these assays can truly be considered a ‘gold standard’. Significant associations between clinical progression, viral sequence-based predictors of co-receptor usage and the output of recombinant assays are observed, suggesting that sensitivity can be improved by incorporating CD4% into genotype-based predictors. This is verified with a SVM model which showed a 17% increase in sensitivity when CD4% was incorporated into training and testing. Conclusion: This work in this thesis has exposed the difficulty in determining the co-receptor phenotype in the clinical setting, primarily due to minority species. Although genotypic methods of screening for HIV co-receptor usage prior to the administration of CCR5 antagonists may reduce costs and increase turn-around time over phenotypic methods, they are currently inadequate for use in the clinical setting due to low sensitivities. Although the addition of clinical parameters such as CD4 count significantly increases the predictive ability of genotypic methods, the presence of low-levels of X4 virus continues to reduce the sensitivity of both genotypic and phenotypic methods.

Objective: The human immunodeficiency virus type 1 (HIV-1) currently infects over 30 million people worldwide. It uses one of two main co-receptors to infect cells. The primary objective of this thesis is to evaluate genotypic and phenotypic assays for co-receptor usage in the clinical setting and investigate approaches for improvement of these assays. Methods: The concordance of recombinant co-receptor phenotyping assays and the predictive ability of genotype-based methods including the ‘11/25’ rule, position specific scoring matrices (PSSMs), and support vector machines (SVMs) were evaluated in the clinical setting using patient-derived plasma samples. Samples and patient data were evaluated in cross-sectional analyses from a retrospective population-based cohort of HIV-infected individuals enrolled in the HIV/AIDS Drug Treatment Program in British Columbia, Canada. Results: Current implementations of HIV V3 region-based predictors for HIV co-receptor usage tested on patient derived samples are inadequate in the clinical setting, primarily due to low sensitivities as a result of difficult to detect minority species. Recombinant phenotype assays also show discordances when tested against each other on the same set of patient derived samples, raising doubts if any of these assays can truly be considered a ‘gold standard’. Significant associations between clinical progression, viral sequence-based predictors of co-receptor usage and the output of recombinant assays are observed, suggesting that sensitivity can be improved by incorporating CD4% into genotype-based predictors. This is verified with a SVM model which showed a 17% increase in sensitivity when CD4% was incorporated into training and testing. Conclusion: This work in this thesis has exposed the difficulty in determining the co-receptor phenotype in the clinical setting, primarily due to minority species. Although genotypic methods of screening for HIV co-receptor usage prior to the administration of CCR5 antagonists may reduce costs and increase turn-around time over phenotypic methods, they are currently inadequate for use in the clinical setting due to low sensitivities. Although the addition of clinical parameters such as CD4 count significantly increases the predictive ability of genotypic methods, the presence of low-levels of X4 virus continues to reduce the sensitivity of both genotypic and phenotypic methods.

Objective: The human immunodeficiency virus type 1 (HIV-1) currently infects over 30 million people worldwide. It uses one of two main co-receptors to infect cells. The primary objective of this thesis is to evaluate genotypic and phenotypic assays for co-receptor usage in the clinical setting and investigate approaches for improvement of these assays. Methods: The concordance of recombinant co-receptor phenotyping assays and the predictive ability of genotype-based methods including the ‘11/25’ rule, position specific scoring matrices (PSSMs), and support vector machines (SVMs) were evaluated in the clinical setting using patient-derived plasma samples. Samples and patient data were evaluated in cross-sectional analyses from a retrospective population-based cohort of HIV-infected individuals enrolled in the HIV/AIDS Drug Treatment Program in British Columbia, Canada. Results: Current implementations of HIV V3 region-based predictors for HIV co-receptor usage tested on patient derived samples are inadequate in the clinical setting, primarily due to low sensitivities as a result of difficult to detect minority species. Recombinant phenotype assays also show discordances when tested against each other on the same set of patient derived samples, raising doubts if any of these assays can truly be considered a ‘gold standard’. Significant associations between clinical progression, viral sequence-based predictors of co-receptor usage and the output of recombinant assays are observed, suggesting that sensitivity can be improved by incorporating CD4% into genotype-based predictors. This is verified with a SVM model which showed a 17% increase in sensitivity when CD4% was incorporated into training and testing. Conclusion: This work in this thesis has exposed the difficulty in determining the co-receptor phenotype in the clinical setting, primarily due to minority species. Although genotypic methods of screening for HIV co-receptor usage prior to the administration of CCR5 antagonists may reduce costs and increase turn-around time over phenotypic methods, they are currently inadequate for use in the clinical setting due to low sensitivities. Although the addition of clinical parameters such as CD4 count significantly increases the predictive ability of genotypic methods, the presence of low-levels of X4 virus continues to reduce the sensitivity of both genotypic and phenotypic methods. / Medicine, Faculty of / Medicine, Department of / Experimental Medicine, Division of / Graduate

The main benefit of the work is the optimization of the hardware configuration for the calculation of neural networks. The theoretical part describes neural networks, deep learning frameworks and hardware options. The next part of the thesis deals with implementation of performance tests, which include application of Inception V3 and ResNet models. Network models are applied to various graphics cards and computing hardware. The output of the thesis is the implemented model of the network Inception V3, which examines the graphics cards and their performance, time-consuming calculations and their efficiency. The ResNet model is applied to a section that examines other impacts on neural network computing such as used disk, operating memory, and so on. Each practical part contains a discussion where the knowledge of the given part is explained. In the case of consumption measurement, a mismatch between the declaration by the manufacturer and the measured values was identified.

The submitted thesis is concerned with a design of the multiplicator of memory cards. The basic focus of this thesis is the analysis of individual system components and adjustment of the existing arrangement. The analysis describes the existing arrangement of the multiplicator and deals with the potential of individual components. Adjustment of the existing arrangement includes definitions and processes of the individual multiplicator components design to the achievement of optimal performance. Operating of the multiplicator is fully controlled by a PC.

Nagrinėjama skirtingais medicinos informatikos standartais ar jų skirtingomis versijomis sąveikaujančių asmens sveikatos priežiūros įstaigos informacinių sistemių integracija. Pagal Kauno Dainavos poliklinikos informacinių sistemų integracijos uždavinius pasirinktas artimiausias teorinis integracijos modelis. Jo pagrindu parengti tarpinio (integracinio) IS sluoksnio/modulio funkciniai reikalavimai, užtikrinantys vienareikšmius paciento sąryšius su jo sveikatos duomenimis, esančiais skirtingose sistemose. Panaudojant medicinos informatikos standarto HL7 bibliotekas 2-ai ir 3-iai versijoms, sukurtas ir sėkmingai išbandytas tarpinio (integracinio) IS sluoksnio/modulio prototipas, leidžiantis automatiškai formuoti procedūrų užsakymo identifikatorius ir, jų pagrindu, nuorodas į duomenų archyvą. Integralumas tarp 2-os ir 3-os versijos sutampančių komponentų užtikrinamas trigeriais: įterpiant, keičiant bei trinant įrašus iš vietos versijos komponento, jis bus atitinkamai modifikuotas ir kitoje versijoje. Toks duomenų sluoksnio realizavimas leidžia sumažinti verslo logikos sluoksnio sudėtingumą, kai naudojama trijų lygių architektūra, bei pačių duomenų transformacijų skaičių. / The research is devoted to an integration of health information systems, when the interoperability should be utilised using different health informatics standards or their versions. To meet the integration goals, the theoretical model, closest to a particular situation of the Dainava outpatient clinic in Kaunas, had been chosen. Based on the model, the functional requirements for the middleware (integration) layer had been defined in order to ensure unambiguous links between patient data, stored in different systems. The middleware software prototype had been developed using messaging libraries for the HL7 versions v2 and v3. The middleware was successfully tested for automatic generation of orders for procedures and links to the procedure result data in the archive. The integration of the HL7 v2 and v3 coincidental components is achieved using trigger events for synchronous data manipulations. Such rules, implemented at the data layer, leads to less complex logics at business process layer and to lower number of data transformations. After automatic orders generation from referrals model implementation, we had to produce Worklist management system prototype to ensure full control of coming patient examinations. In this scenario DICOM based data models and terms had been chosen to use.

La première étape du cycle viral du virus de l'immunodéficience humaine se déroule grâce à l'interaction entre les glycoprotéines d'enveloppe gp120/gp41 et les récepteurs CD4 et CCR5/CXCR4. Les différentes fonctions activées par cette étape, incluant l'attachement, la pénétration et la signalisation cellulaire représentent des cibles potentielles pour le développement d'antirétroviraux. Dans ce travail, nous avons développé des approches permettant d'agir sur chacune de ces étapes à l'aide de peptides synthétiques, d'anticorps anti-peptide et d'inhibiteurs des voies de signalisation. Dans la première approche, nous nous sommes intéressé au développement d'analogues peptidiques de la région HRII en évitant les limitations, incluant courte demi-vie et émergence d'isolats de résistance, rencontrées lors de l'utilisation du peptide T-20 (Fuzeon). Nous avons synthétisé un peptide de 34 acides aminés modélisant la région HRII en incluant des acides aminés non naturels de série D uniquement au niveau de certains sites sensibles à la protéolyse ou dans la totalité de la séquence.Les résultats obtenus montrent que les modifications ponctuelles permettent de : i) maintenir la structure en hélice a du peptide, ii) maintenir sa capacité à interagir avec la région HRI, iii) d'augmenter sa demie-vie et iv) de conserver son activité antivirale. Dans la deuxième approche, nous avons testé la capacité des peptides analogues de la région HRII de VIH-1 et de la boucle V3 de SIV à induire la production d'anticorps neutralisants. Cette étude nous a permis d'aboutir à deux conclusions principales : i) les anticorps anti-HRII peuvent interférer avec l'activité antivirale du peptide administré lors du traitement antiviral, ii) contrairement aux anticorps anti-V3 du VIH-1, les anticorps anti-V3 de SIV sont incapables de neutraliser le virus SIV suggérant des fonctions différentes pour cette région chez HIV-1 et SIV. Dans la troisième partie, nous avons montré que l'attachement du virus VIH sur son récepteur s'accompagne de l'activation de la voie PKC dont l'isoforme PKC-d. L'inhibition de cet isoforme bloque totalement la réplication virale. Ce blocage semble s'opérer en interférant avec les étapes post-entrée du virus en inhibant la formation des pseudopodes et des filaments d'actine, structure nécessaire pour l'étape de la transcription inverse.

Η παρεμπόδιση της μόλυνσης ενός κυττάρου από τον HIV επιτυγχάνεται ή με αναστολή της αλληλεπίδρασης της ιικής gp120 με τους CD4 υποδοχείς των κυττάρων, είτε παρεμποδίζοντας τη δράση της gp41 ή τέλος αποτρέποντας τη σύζευξη της gp120 με τους CXCR4 και CCR5 υποδοχείς των χημειοκινών. Ο ρόλος όμως των χημειοκινών και των υποδοχέων τους στη διαδικασία μετάδοσης σημάτων, μέσω των οποίων ενεργοποιούνται αποπτωτικοί μηχανισμοί υγιών, μη μολυσμένων από τον HIV κυττάρων, καθιστά την gp120-CCR5/CXCR4 αλληλεπίδραση ιδιαίτερα θελκτικό επιστημονικά στόχο για το σχεδιασμό αναστολέων του κύκλου αναπαραγωγής του ιού. Σύμφωνα με πλήθος ανοσολογικών, φυσικοχημικών και δομικών μελετών η PND V3 περιοχή της gp120 και το εξωκυττάριο αμινο-τελικό πεπτιδικό τμήμα του CCR5 συνυποδοχέα αποτελούν τις κυρίως εμπλεκόμενες περιοχές στην αλληλεπίδραση των δύο πρωτεϊνών. Η μεταβλητότητα της PND V3 ακολουθίας και ο συσχετισμός της με την υιοθετούμενη διαμόρφωση, η σύνδεση της θέσης και του είδους των αμινοξέων με την ένταση της αλληλεπίδρασης και η συνάρτηση του ιικού τροπισμού με τη βιολογικά ενεργή διαμόρφωση των πεπτιδίων αποτελούν θεμελιώδη στάδια στη διαδικασία κατανόησης του μηχανισμού αλληλεπίδρασης της gp120 με τον CCR5 κυτταρικό συνυποδοχέα και των παραγόντων που την καθορίζουν. Προς αυτή την κατεύθυνση εστιάστηκε και το ενδιαφέρον της διατριβής έχοντας ως πρωτογενείς στόχους την αποτίμηση των καθοριστικών παραγόντων της αλληλεπίδρασης χρησιμοποιώντας πεπτιδικά τμήματα των πρωτεϊνών, τον προσδιορισμό του είδους της και την επίλυση της δομής των συγκεκριμένων τμημάτων μέσω Φασματοσκοπίας Πυρηνικού Μαγνητικού Συντονισμού. Όπως ήταν αναμενόμενο για ελεύθερα, μικρά σε μέγεθος μόρια που είναι διαλυμένα σε νερό, τα PND V3 πεπτίδα εμφάνισαν την ιδιότητα της διαμορφωτικής ελευθερίας αλλά παρουσίασαν σημαντικό αριθμό NOE συζεύξεων, γεγονός το οποίο επέτρεψε τη σύγκλισή τους προς μία συγκεκριμένη διαμόρφωση. Η διαμόρφωση τύπου U, η οποία είχε παρατηρηθεί στις κρυσταλλικές δομές συμπλόκων της gp120, διατηρείται ανεξαρτήτως της παρουσίας του CCR5. Τα αποτελέσματα των πειραμάτων της φασματοσκοπίας NMR υποδεικνύουν την ύπαρξη ασθενούς ηλεκτροστατικής αλληλεπίδρασης μεταξύ των PND V3 πεπτιδίων και του CCR5Nt. Η συμμετοχή των πεπτιδικών τμημάτων του CCR5Nt στην αλληλεπίδραση αυξάνει προοδευτικά και φαίνεται να είναι ανάλογη του αριθμού των θετικά φορτισμένων αμινοξέων της ακολουθίας των PND V3 πεπτιδίων και προφανέστατα εξαρτώμενη από την κατιονική τους δύναμη. Τα συμπεράσματα της διατριβής σε συνδυασμό με εκείνα που παράγονται από πλήθος βιολογικών, βιοχημικών και φυσικοχημικών μελετών παράγουν νέα δεδομένα, τα οποία δύναται να χρησιμοποιηθούν στον ορθολογικό σχεδιασμό αναστολέων με αυξημένη συγγένεια δέσμευσης στον συνυποδοχέα CCR5. / The obstruction of a cell infection by HIV is succeeded either by inhibiting the interaction between the viral gp120 and the CD4 cell receptors or by preventing the gp41 action and deterring the conjuction of gp120 with the CXCR4 and CCR5 chemokine receptors. The role that chemokines and their receptors play at the process of signal transmission, through which the apoptotic mechanisms of non HIV infected cells are activated, appoints the gp120-CCR5/CXCR4 interaction as a highly attractive scientific target for the design of HIV-1 life cycle inhibitors. According to numerous immunological, physicochemical and structural studies the PND V3 region of gp120 and the extracellular N-terminal peptide fragment of CCR5 coreceptor constiture the primary regions that are involved in the interactions of occurring between the two proteins. The sequence variation of the PND V3 region and its correlation with the adopted conformation, the dependence of the position and type of amino-acid with the intensity of the interaction and the linkage of viral tropism with the peptides biologically active conformation comprise fundamental stages in the process of understanding the mechanism of gp120 – CCR5 interaction and the elements that designate it. The thesis interest was oriented towards this direction while its primary targets were the evaluation of the interaction determinants by using peptide fragments, the designation of the interaction type and the calculation of the specific peptides structures through the use of Nuclear Magnetic Resonance Spectroscopy. As expected for free peptides in solution, the peptides representing the PND V3 region of gp120 exhibit conformational flexibility, but they exhibited a large number of NOEs which allowed convergence to a specific conformation. The PND V3 peptides retain the U-turn conformation observed in the crystal structures of gp120 complexes independently of CCR5 presence. The interaction of different regions of the CCR5Nt peptide is gradually increasing proportionally to the positive charge increase in the V3 peptides. The data demonstrate that the PND V3 and CCR5Nt peptide sequences have propensities for interaction and that their binding and selectivity is determined by simple electrostatic attraction mechanisms. The thesis conclusions combined to those extracted by many biological, biochemical and physicochemical studies bring forth new data that can be used in the rational design of inhibitors that will exhibit increased binding affinity for CCR5 co-receptor.